<code id='B7C2BFC4D8'></code><style id='B7C2BFC4D8'></style>
    • <acronym id='B7C2BFC4D8'></acronym>
      <center id='B7C2BFC4D8'><center id='B7C2BFC4D8'><tfoot id='B7C2BFC4D8'></tfoot></center><abbr id='B7C2BFC4D8'><dir id='B7C2BFC4D8'><tfoot id='B7C2BFC4D8'></tfoot><noframes id='B7C2BFC4D8'>

    • <optgroup id='B7C2BFC4D8'><strike id='B7C2BFC4D8'><sup id='B7C2BFC4D8'></sup></strike><code id='B7C2BFC4D8'></code></optgroup>
        1. <b id='B7C2BFC4D8'><label id='B7C2BFC4D8'><select id='B7C2BFC4D8'><dt id='B7C2BFC4D8'><span id='B7C2BFC4D8'></span></dt></select></label></b><u id='B7C2BFC4D8'></u>
          <i id='B7C2BFC4D8'><strike id='B7C2BFC4D8'><tt id='B7C2BFC4D8'><pre id='B7C2BFC4D8'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:97
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          J&J to emphasize cancer drugs, stop much of its vaccine research
          J&J to emphasize cancer drugs, stop much of its vaccine research

          DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Rep. Raul Ruiz on the physician shortage and more

          BeforehejoinedCongress,Rep.RaulRuiz,aDemocratfromCalifornia,workedinanotherchaoticenvironment:theeme